The UK's Advisory Committee on Novel Foods and Processes (ACNFP) has provisionally approved the use of two CBD extracts in food supplements, marking a significant development in the regulatory landscape for cannabidiol products.
Synthetic Cannabidiol Approved for Food Supplements
In January 2021, Chanelle McCoy CBD Ltd. submitted an application to both the Food Standards Agency (FSA) and Food Standards Scotland (FSS) seeking authorization for their synthetic cannabidiol as a novel food. This CBD form boasts a purity of over 98% and is designed for adult consumption in oil-based capsules and drops, with a recommended dosage of 10 mg per day. The ACNFP has confirmed the safety of this product for the proposed use, noting that its consumption at the anticipated levels is not nutritionally disadvantageous.
Cannabidiol Isolate Clears Committee Review
Following a similar application process in February 2021 by Cannaray Brands Ltd., cannabidiol isolate has also received a positive assessment. This substance, also over 98% pure, is extracted from industrial hemp through a meticulous multi-step process and is intended for use in food supplements, beverages, and confectionery for adults. Echoing the sentiments for synthetic cannabidiol, the committee has assured the safety of cannabidiol isolate under its intended conditions of use.
Impact and Next Steps
These approvals represent the first of their kind in the UK for CBD as a novel food ingredient. Both Chanelle McCoy CBD Ltd. and Cannaray Brands Ltd. have adhered to the guidelines set by both the ACNFP and the Committee on Toxicity, which includes the stipulation of a 10 mg daily dose of CBD.
Currently, these ingredients are already marketable in England and Wales under transitional arrangements, with specific reference numbers RP07 and RP350. Official authorization as novel foods is expected soon, after which they will be added to the Register of Novel Foods Authorisations.
These initial approvals in the UK could potentially influence the European Food Safety Authority (EFSA) as it continues to assess other CBD applications across Europe. Presently, 23 applications are under review, with decisions on five expected by late 2024.
